Detail akcie Heron Therapeutics online

Business Summary: Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Heron Therapeutics Inc revenues increased 18% to $127M. Net loss decreased 39% to $110.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects "Research and development - Balancing va decrease of 65% to $19.8M (expense), Sales and marketing - Balancing value decrease of 16% to $58.1M (expense).